Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.57 |
| ▸ | ALPL | P05186 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979120 | 0.80 | DCUN1D1 (0.56) | DCUN1D1ALPLLMNAALPGMAPT | |
| SCHEMBL7522449 | 0.73 | DCUN1D1 (0.52) | DCUN1D1ALPLLMNAALPGMAPT | |
| SCHEMBL6696853 | 0.66 | DCUN1D1 (0.66) | DCUN1D1ALPLLMNAALPGALDH1A1 | |
| SCHEMBL10944351 | 0.64 | NR1H2 (0.77) | DCUN1D1ALPLALPGALDH1A1 | |
| SCHEMBL1528199 | 0.63 | ALPL (0.61) | ALPLLMNAALPGMAPT | |
| SCHEMBL8725571 | 0.63 | DCUN1D1 (0.62) | DCUN1D1ALPLMAPTALDH1A1 | |
| 1,2-Dichlorobenzene SCHEMBL28133202 | 0.63 | TSHR (0.56) | LMNAMAPTPOLBALDH1A1 | |
| SCHEMBL8841399 | 0.62 | DCUN1D1 (0.51) | DCUN1D1ALPLALPGMAPTALDH1A1 | |
| SCHEMBL1528139 | 0.61 | ALPL (1.00) | DCUN1D1ALPLLMNAALPGMAPT | |
| SCHEMBL29535326 | 0.61 | DCUN1D1 (0.50) | DCUN1D1ALPLLMNAALPGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109790-B1 | 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| US-20020086862-A1 | Novel compounds | ASTRAZENECA AB | 2002-07-04 | — | — | US | disclosed |
| EP-1109790-A1 | 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012489-A1 | 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086862-A1 | Novel compounds | ABCG2, CYP3A4, CYP4B1 | DCUN1D1 2840/4885ALPL 4282/4885LMNA 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.